Opendata, web and dolomites

TRS SIGNED

A paradigm change in the treatment of blinding ocular diseases

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TRS project word cloud

Explore the words cloud of the TRS project. It provides you a very rough idea of what is the project "TRS" about.

mechanism    iia    expand    engineer    grant    us    risk    autoimmune    pipeline    gt    reinvested    believe    500    first    launch    tarsius    commercialization    2024    post    drug    capability    impose    diseases    selecting    strategy    disrupt    700    tax    causes    steroids    re    billion    urgent    shares    approved    gain    2028    steroid    orphan    people    glaucoma    molecule    bio    hundreds    economic    global    disease    company    merely    safe    preclinical    exceed    requiring    class    lasting    secure    candidate    25    burden    unmet    clinical    relieve    shorter    trial    market    millions    treat    array    worldwide    time    uveitic    correspond    revenue    patients    treating    therapeutic    saving    inflammation    infectious    society    devastating    medical    extended    effect    platform    inflammatory    broad    penetration    inspired    reliefs    immune    local    blindness    exclusivity    corticosteroids    indication    ocular    symptoms    profits    perform    treatment    itself    excellent    financing   

Project "TRS" data sheet

The following table provides information about the project.

Coordinator
TARSIUS PHARMA LTD 

Organization address
address: 19 YAHALOM ST.
city: ZICHRON YAAKOV
postcode: 3093765
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 3˙461˙500 €
 EC max contribution 2˙423˙050 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-07-01   to  2021-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TARSIUS PHARMA LTD IL (ZICHRON YAAKOV) coordinator 2˙423˙050.00

Map

 Project objective

Ocular inflammatory diseases – affecting hundreds of millions of people worldwide – impose a significant medical and economic burden on society and can lead to blindness. Today, corticosteroids are the most common method used to treat ocular non-infectious inflammation of any kind. Rather than treating the disease itself, however, steroids merely relieve its symptoms, and long-term use can result in devastating consequences. Our bio-inspired drug candidate is a non-steroid. It approaches inflammatory diseases from within the immune system and was developed to ‘re-engineer’ the immune system. Based on excellent preclinical results, we believe that this approach will have the capability to disrupt the immune mechanism that causes the disease in order to provide patients with a safe and long-lasting therapeutic effect, with the goal of saving them from blindness. Our platform technology has the potential to effectively treat a broad array of autoimmune and inflammatory diseases and to become a first in class, market approved molecule for local treatment of inflammatory ocular diseases. Our first target indication is uveitic glaucoma – a devastating orphan disease requiring urgent treatment and carrying high risk of blindness. Selecting an orphan indication as a market penetration strategy will grant us extended market exclusivity, tax reliefs and shorter time to market. In the project, we will perform a Phase I/IIa clinical trial. We will exploit the trial results to secure financing for further clinical development towards commercialization. The global ocular inflammation treatment market is expected to exceed more than US$ 500 Billion by 2024. As our first target indication has a significant unmet need with no approved treatment, we expect to gain 25% of market shares 5 years post launch, which would correspond to >€700 M in revenue for Tarsius in 2028 for uveitic glaucoma only. Profits will be reinvested to develop our product pipeline and expand our company.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TRS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TRS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

ECOBIOMASS (2019)

Achieving unique wines through an efficient production process

Read More  

DetectInMen (2019)

Infection detection in human semen

Read More  

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More